PHAXIAM Therapeutics SA

PHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024

05 Dec 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

27 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

18 Nov 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Reports Third-Quarter 2024 Financial Information

13 Nov 2024 10:45:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2024

08 Nov 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.

04 Nov 2024 11:00:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – October 8, 2024

10 Oct 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 study

09 Oct 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Provides Business and Financial Update For the First Half of 2024

25 Sep 2024 10:45:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – July 1, 2024

03 Jul 2024 11:00:00 By Nasdaq GlobeNewswire

Results of the Combined General Meeting of 28 June 2024

28 Jun 2024 10:45:00 By Nasdaq GlobeNewswire

PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024

07 Jun 2024 10:45:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – May 31, 2024

05 Jun 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM provides Business and Financial Update for the First Quarter of 2024

15 May 2024 10:45:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024

03 May 2024 11:05:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus

15 Apr 2024 00:30:00 By Nasdaq GlobeNewswire

Monthly information related to total number of voting rights and shares composing the share capital – March 29, 2024

09 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)

05 Apr 2024 11:00:00 By Nasdaq GlobeNewswire

PHAXIAM Announces 2023 Full-Year Results and Provides Business Update

20 Mar 2024 12:00:00 By Nasdaq GlobeNewswire

PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market

11 Mar 2024 01:00:00 By Nasdaq GlobeNewswire